ImmunityBio locks trial database: ImmunityBio stock draws six Buy ratings

Published on 10/27/2026 at 22:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Final analysis targets November 2026 after 366 patients entered the trial. ImmunityBio stock costs EUR 7.77 on October 27, 2026, with USD 9.1 billion market cap.

Trial progress and valuation

ImmunityBio completed database lock for a 366-patient trial on October 21, 2026.
Second-quarter revenue reached USD 51.24 million, while GAAP loss per share was USD 0.22.
ImmunityBio stock costs EUR 7.77 at Lang & Schwarz on October 27, 2026 at 10:46 p.m. CEST.
Third-quarter results are scheduled for November 3, 2026.

IBRX, US45256X1037, Illustration mit AI erstellt.

ImmunityBio (US45256X1037) completed database lock for a 366-patient registrational trial on October 21, 2026, according to ImmunityBio. The final analysis of ANKTIVA plus BCG is underway, with topline results expected in November 2026. ImmunityBio was trading at EUR 7.77 at Lang & Schwarz on October 27, 2026 at 10:46 p.m. CEST.

Trial analysis moves closer

The QUILT-2.005 study compares ANKTIVA plus BCG with BCG alone in patients receiving BCG treatment for the first time. The database lock followed review and reconciliation of all 366 randomized patients, allowing the primary efficacy analysis to proceed.

The company also said its supplemental biologics license application remains on track for the fourth quarter of 2026. The filing could seek an expanded ANKTIVA indication for patients with non-muscle-invasive bladder cancer earlier in their treatment journey.

What November 3 could clarify

MarketBeat identifies November 3, 2026 as the scheduled date for ImmunityBio's third-quarter results. The same report cites consensus revenue of USD 59.23 million and a projected loss of USD 0.07 per share.

Revenue growth meets a large loss

For the second quarter ended June 30, 2026, revenue was USD 51.24 million, while GAAP loss per share was USD 0.22 against a consensus loss of USD 0.08, according to MarketBeat. The company reported USD 51.24 million in revenue versus expectations of USD 49.70 million. The result leaves the November report as the next dated test for sales growth and operating costs.

Biotech peers set a wider frame

ImmunityBio had a market capitalization of USD 9.1 billion and a negative trailing price-to-earnings ratio of 8.86 as of October 27, 2026. Moderna had a USD 83.0 billion market capitalization and a negative price-to-earnings ratio of 26.06, while BioNTech had USD 21.9 billion and a negative ratio of 11.53 on the same date.

Stock price and next date

ImmunityBio's primary listing is on Nasdaq, where the stock's 52-week range was USD 1.95 to USD 12.43 as of October 27, 2026. The next scheduled company date is November 3, 2026, when third-quarter results are expected before the market opens.

The further course of trading is shown by the continuously updated real-time quote of ImmunityBio stock.